Cetera Advisors LLC Has $5.66 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Cetera Advisors LLC lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 593.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 40,808 shares of the medical device company’s stock after buying an additional 34,923 shares during the period. Cetera Advisors LLC’s holdings in DexCom were worth $5,660,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Team Hewins LLC grew its stake in DexCom by 3.4% during the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after buying an additional 83 shares in the last quarter. Bleakley Financial Group LLC lifted its stake in DexCom by 1.3% during the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after purchasing an additional 87 shares during the last quarter. D Orazio & Associates Inc. boosted its holdings in shares of DexCom by 0.8% in the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after purchasing an additional 93 shares in the last quarter. Gulf International Bank UK Ltd increased its stake in shares of DexCom by 0.3% in the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after purchasing an additional 93 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of DexCom by 10.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock worth $133,000 after buying an additional 98 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 427 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $49,126.35. Following the completion of the sale, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at $8,729,648.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other DexCom news, EVP Sadie Stern sold 427 shares of DexCom stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the transaction, the executive vice president now owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the sale, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,135 shares of company stock valued at $446,797. 0.30% of the stock is owned by company insiders.

DexCom Stock Up 2.8 %

Shares of DXCM traded up $1.98 during trading hours on Friday, reaching $72.30. The stock had a trading volume of 7,633,973 shares, compared to its average volume of 7,607,828. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The firm has a 50-day simple moving average of $109.33 and a 200 day simple moving average of $121.82. The company has a market capitalization of $28.97 billion, a price-to-earnings ratio of 46.65, a P/E/G ratio of 2.18 and a beta of 1.16. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.34 EPS. Equities research analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Raymond James raised their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Baird R W downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Wells Fargo & Company cut their target price on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research report on Friday, July 26th. Finally, Royal Bank of Canada dropped their target price on DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $111.50.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.